Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP41
- Development stage
- Unknown
- Lead developer
- Serpin Pharma
- Modality
- Peptides
- Administration
- Subcutaneous, Topical
01
Overview
SP41 is a synthetic peptide therapeutic being developed by Serpin Pharma for the treatment of severe skin diseases. It is part of a pipeline of peptides derived from the anti-inflammatory and immune-modulating protein Alpha-1 Antitrypsin (AAT). SP41 is designed to leverage the body's natural pro-resolving pathways to treat inflammatory and autoimmune conditions. While specific details on its molecular structure are proprietary, it belongs to a class of peptides developed by Serpin Pharma that typically target the Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) to resolve inflammation without causing broad immunosuppression. The drug is currently in Phase 1 clinical development.
Beyond the preview
Go deeper on SP41.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP41.